European Journal of Nuclear Medicine and Molecular Imaging

Papers
(The H4-Index of European Journal of Nuclear Medicine and Molecular Imaging is 58. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
18F-FDG brain PET hypometabolism in patients with long COVID300
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET217
International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres162
Clinical performance of long axial field of view PET/CT: a head-to-head intra-individual comparison of the Biograph Vision Quadra with the Biograph Vision PET/CT153
The EANM practice guidelines for parathyroid imaging136
Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients131
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0122
Long COVID hallmarks on [18F]FDG-PET/CT: a case-control study112
Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT112
EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3107
The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study107
68Ga-FAPI-PET/CT in patients with various gynecological malignancies105
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands98
Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers98
Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation97
Cellular sources of TSPO expression in healthy and diseased brain95
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds94
Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT91
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers89
Deep learning-assisted ultra-fast/low-dose whole-body PET/CT imaging89
Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy89
State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis89
Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imagin83
Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model82
Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI82
EANM procedural guidelines for PET/CT quantitative myocardial perfusion imaging81
Total-body PET/CT using half-dose FDG and compared with conventional PET/CT using full-dose FDG in lung cancer77
PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports75
18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma71
HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging70
A head-to-head comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study70
Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging69
Large language models (LLM) and ChatGPT: what will the impact on nuclear medicine be?69
Radiomics analysis of [18F]FDG PET/CT for microvascular invasion and prognosis prediction in very-early- and early-stage hepatocellular carcinoma69
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)68
Diagnostic value of [18F]FDG-PET/CT for treatment monitoring in large vessel vasculitis: a systematic review and meta-analysis68
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy67
Transpathology: molecular imaging-based pathology67
Head-to-head comparison of [68Ga]Ga-FAPI-04 and [18F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma67
Structural and functional radiomics for lung cancer66
Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis65
Brain 18F-FDG PET for the diagnosis of autoimmune encephalitis: a systematic review and a meta-analysis65
Value of [68Ga]Ga-FAPI-04 imaging in the diagnosis of renal fibrosis65
Quantification of amyloid PET for future clinical use: a state-of-the-art review65
[18F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [68Ga]Ga-FAPI-0463
Long axial field of view PET scanners: a road map to implementation and new possibilities63
The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent—comparison with [18F]FDG62
Ultra-low-activity total-body dynamic PET imaging allows equal performance to full-activity PET imaging for investigating kinetic metrics of 18F-FDG in healthy volunteers62
Similar patterns of [18F]-FDG brain PET hypometabolism in paediatric and adult patients with long COVID: a paediatric case series62
[153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma62
CXCR4-targeted theranostics in oncology62
First results on kinetic modelling and parametric imaging of dynamic 18F-FDG datasets from a long axial FOV PET scanner in oncological patients61
[11C]MODAG-001—towards a PET tracer targeting α-synuclein aggregates60
Joint EANM/SNMMI guideline on radiomics in nuclear medicine60
Comparison of [68 Ga]Ga-FAPI-04 and [18F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study59
Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.059
Diagnostic value of [18F]FDG-PET/CT in polymyalgia rheumatica: a systematic review and meta-analysis59
Hybrid total-body pet scanners—current status and future perspectives58
Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond58
0.061680793762207